Document is current
Any future updates will be listed below
-
Authors
Aymerich, Claudia https://orcid.org/0000-0003-0040-1608
Torres-Cortés, Javier
Melillo, Antonio https://orcid.org/0000-0002-1477-7916
Pedruzo, Borja
Catalan, Ana https://orcid.org/0000-0002-0418-7904
Ibarretxe, Olatz https://orcid.org/0009-0008-7192-5680
Nosarti, Chiara https://orcid.org/0000-0001-6305-9710
Rubia, Katya https://orcid.org/0000-0002-1410-7701
Arango, Celso https://orcid.org/0000-0003-3382-4754
Shaw, Philip https://orcid.org/0000-0002-1313-2526
Ani, Cornelius
Huang, Hannah Chu-Han
Dubicka, Bernadka https://orcid.org/0000-0002-8907-8589
Kelleher, Ian https://orcid.org/0000-0003-1484-651X
Fusar-Poli, Paolo
Cortese, Samuele https://orcid.org/0000-0001-5877-8075
Salazar de Pablo, Gonzalo https://orcid.org/0000-0002-6992-0767
- License Information
-
More Information
Article History
Received: 8 September 2025
Accepted: 3 August 2026
First Online: 31 August 2026
Ethics
Competing interests: C. Aymerich received personal fees or grants from Janssen-Cilag and Neuraxpharm outside the current work. A.C. reports grants and personal fees from the Instituto de Salud Carlos III. She has also received research support from the Basque Government and honoraria from Janssen-Cilag, ROVI, Otsuka and Lundbeck, all outside of the submitted work. K.R. received a grant from TAKEDA for another study, consulting fees from SUPERNUS and speaker’s honoraria from the University La Laguna and the International Congress of Clinical and Health Psychology in Children and Adolescents. C. Arango has been a consultant to or has received honoraria or grants from Abbot, Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen-Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, Takeda and Teva. G.S.d.P. has received honoraria from Janssen-Cilag, Lundbeck and Angelini outside the current work. All other authors report no competing interests.
